An ‘elite’ group of four biologic therapies has been identified as having the best short and long-term efficacy in moderate to severe psoriasis in a network meta-analysis. Risankizumab-rzaa, guselkumab, ixekizumab, and brodalumab were associated with the highest estimated PASI (Psoriasis Area and Severity Index) 90% response rates in an analysis that combined data from 60 ...
Review ranks the 4 most effective biologic therapies for psoriasis
By Michael Woodhead
6 Feb 2020